🔥 HOT FROM ACG 2026 | NASHVILLE Five IBD Studies Worth a Closer Look! Another exciting ACG meeting, another opportunity to reflect on where IBD care is heading. From innovative drug delivery strategies to better symptom control, complex patient populations, and reproductive health, the science continues to evolve. For this special edition of IBD Library™, we invited Dr. @AsadurRahman87 , Medical Director of the IBD Center and Associate Program Director of the GI Fellowship at Cleveland Clinic Florida, to review five interesting studies presented at ACG 2026. 🔬 What's inside? 💉 Subcutaneous vs IV infliximab: Could route of administration influence outcomes in ileal Crohn's disease? 💊 Risankizumab AFFIRM trial: Another step toward an entirely subcutaneous treatment strategy. 🌙 Obefazimod in UC: Because bowel urgency and uninterrupted sleep matter to our patients. 🩺 JAK inhibitors in PSC associated IBD: Exploring options for a particularly challenging population. 👶 Fertility and IBD: Encouraging insights from the WIsDoM cohort on assisted reproductive technology. Innovation in IBD is no longer just about introducing another effective molecule. It is also about how we deliver treatment, what outcomes we prioritize, and how we address the needs of patients often underrepresented in clinical trials. Of course, conference abstracts generate important questions, but not necessarily immediate changes in practice. A special thank you to Dr. Asad ur Rahman for contributing his expertise to this edition of IBD Library™. 📖 Enjoy the review, and let us know: Which of these five studies caught your attention the most? #IBDLibrary #ACG2026 #CrohnsDisease #UlcerativeColitis #IBD #Gastroenterology #ClinicalResearch #MedicalEducation